GWA
TOVX icon

Genesis Wealth Advisors’s Theriva Biologics TOVX Stock Holding History

Genesis Wealth Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$214K Hold
9
– – 0.17% 64
2015
Q1 		$162K Buy
9
+5
+125% +$89.3K 0.13% 75
2014
Q4 		$78.8K Buy
+4
New +$53.7K 0.06% 167

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Genesis Wealth Advisors's TOVX Position: Q2 2015 in Review

Genesis Wealth Advisors held its Theriva Biologics (TOVX) position steady in Q2 2015 at 9 shares worth $214K. The position accounts for 0.17% of the portfolio, ranked #64.

Genesis Wealth Advisors first reported a position in TOVX in Q4 2014 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold TOVX as of Q2 2015.

  • Genesis Wealth Advisors held 9 shares of Theriva Biologics worth $214K as of Q2 2015.
  • Genesis Wealth Advisors left its Theriva Biologics share count unchanged in Q2 2015.
  • Theriva Biologics made up 0.17% of Genesis Wealth Advisors's portfolio in Q2 2015, its #64 holding.
  • Genesis Wealth Advisors first reported a position in Theriva Biologics in Q4 2014 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2015.

Based on Genesis Wealth Advisors's 13F filing for Q2 2015, filed 24 Aug 2015.